Manifold Partners’s West Pharmaceutical WST Stock Holding History

Manifold Partners’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-9,730	Closed	-$738K	–	38
2016 Q2	$738K	Buy	+9,730	New	+$708K	0.59%	23

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Manifold Partners's WST Position: Q3 2016 in Review

Manifold Partners sold out of West Pharmaceutical (WST) in Q3 2016, closing a stake of 9,730 shares — an estimated $738K sold.

Manifold Partners first reported a position in WST in Q2 2016 and held it in 1 quarter. The position peaked at $738K in Q2 2016. 280 funds tracked by Wall St. Rank hold WST as of Q3 2016.

Manifold Partners reported no remaining West Pharmaceutical position as of Q3 2016 after selling out during the quarter.
Manifold Partners sold 9,730 West Pharmaceutical shares in Q3 2016, an estimated $738K.
Manifold Partners first reported a position in West Pharmaceutical in Q2 2016 and held it in 1 quarter.
Manifold Partners's West Pharmaceutical position peaked at $738K in Q2 2016.
280 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2016.

Based on Manifold Partners's 13F filing for Q3 2016, filed 8 Nov 2016.